Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Ramipril

Ramipril

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor medication used to treat hypertension, heart failure, and diabetic kidney disease.
It works by relaxing blood vessels and reducing the workload on the heart.
PubCompare.ai helps researchers optimize Ramipril protocols by locating the most effective approaches from literature, pre-prints, and patents.
Its AI-driven comparisons identify the best protocols and products, enhancing the research process.
Explore the power of AI-driven research protocol enhancement with PubCompare.ai to optimize your Ramipril studies.

Most cited protocols related to «Ramipril»

1
Longitudinal Study of Gut Microbiome Changes During Antibiotic Therapy
Cited 6 times
Fresh faecal samples were collected from a patient who had not taken ABs within the previous 3 months. The patient (a 68-year-old man) was admitted to the Department for Internal Medicine at the University Hospital Kiel (Germany) due to an infected cardiac pacemaker. A clinical examination identified inflamed skin and subcutaneous tissue around the pacemaker, and laboratory findings revealed an elevated C-reactive protein level (CRP 19.7 mg/litre; normal value <8 mg/litre) and a full blood count within normal ranges. The patient did not present any intestinal disorders. The pacemaker had been placed to treat the patient's sick sinus syndrome, first diagnosed in 1994. His cardiovascular risk factors were arterial hypertension and non-insulin-dependent diabetes mellitus. The patient was regularly taking amlodipine, ramipril, hydrochlorothiazide and glimepiride on a daily basis and Marcumar according to his international normalised ratio values. AB therapy was initiated with a combined intravenous therapy of ampicillin/sulbactam and cefazolin on the day of admission as a single dose and continued with intravenous cefazolin alone for the next 14 days. The patient's CRP level returned to normal within 1 week after the beginning of AB therapy. Faecal samples were collected on the day of admission, prior to AB treatment (day 0, FS-0), on days 3, 6, 11 and 14 of AB treatment (FS-3, FS-6, FS-11 and FS-14, respectively) and 40 days after AB therapy (FS-40). Fresh faeces were collected, frozen immediately and stored at −80°C until further processing. Informed consent was obtained from the patient, and the study was approved by the Ethical Board of the Medical Faculty of the Christian-Albrecht-University, Kiel, Germany. The patient provided written informed consent. Full descriptions of the materials and methods used for the following are available in the Materials and Methods in the online supplement: nucleic acid and RNA extraction; 16S rDNA and 16S rRNA sequencing; metagenome sequencing; mRNA purification, amplification and sequencing; metagenomic and metatranscriptomic analysis; protein extraction, separation and identification and data processing; and metabolite extraction, separation and identification and data processing. All sequences have been entered in the European Bioinformatics Institute database, under accession number ERP001506.
Pérez-Cobas A.E., Gosalbes M.J., Friedrichs A., Knecht H., Artacho A., Eismann K., Otto W., Rojo D., Bargiela R., von Bergen M., Neulinger S.C., Däumer C., Heinsen F.A., Latorre A., Barbas C., Seifert J., dos Santos V.M., Ott S.J., Ferrer M, & Moya A. (2012). Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut, 62(11), 1591-1601.
Publication 2012
Amlodipine ampicillin-sulbactam Cefazolin Complete Blood Count C Reactive Protein Diabetes Mellitus, Non-Insulin-Dependent Dietary Supplements Europeans Faculty, Medical Feces Freezing glimepiride High Blood Pressures Hydrochlorothiazide International Normalized Ratio Intestinal Diseases Marcoumar Metagenome Nucleic Acids Pacemaker, Artificial Cardiac Patients Physical Examination Proteins Psychotherapy, Multiple Ramipril Recombinant DNA RNA, Messenger RNA, Ribosomal, 16S Sick Sinus Syndrome Skin Subcutaneous Fat Therapeutics
2
Intensive Blood Pressure Control in CKD
Cited 4 times
The study had two phases, an initial trial phase, followed by a cohort phase. The trial phase had a 3-by-2 factorial design. From February 1995 through September 1998, we randomly assigned 1094 patients to receive either intensive blood-pressure control or standard control. The blood-pressure target was a mean arterial pressure of 92 mm Hg or less in the intensive-control group and 102 to 107 mm Hg in the standard-control group. A mean arterial pressure of 92 is lower than the traditional blood-pressure target of 130/80 mm Hg, which is recommended for patients with chronic kidney disease, and a mean arterial pressure of 107 mm Hg corresponds to the traditional blood-pressure target of 140/90 mm Hg.9 (link) We also randomly assigned patients to one of three initial drug therapies: ramipril, an angiotensin-converting–enzyme (ACE) inhibitor; metoprolol, a sustained-release beta-blocker; or amlodipine, a dihydropyridine calcium-channel blocker. If the blood-pressure target could not be achieved with the highest tolerated dose of the randomly assigned drug, other antihypertensive drugs (furosemide, doxazosin, clonidine, and hydralazine or minoxidil) were sequentially added.
The cohort phase was initiated in April 2002. Between the end of the trial phase on September 30, 2001, and the start of the cohort phase, there was a brief transition period during which the cohort phase was designed and patients were switched from randomized therapy to ramipril. Patients in whom ESRD had not been diagnosed were invited to enroll in the cohort phase, in which they received protocol-driven blood-pressure management on the basis of the results of the primary trial. If patients could not tolerate ramipril therapy, they were switched to an angiotensin-receptor blocker (ARB) that was selected by the clinical site investigator. If the blood-pressure target was not achieved with the highest tolerated dose of ramipril, additional drugs were added, including furosemide, beta-blockers, calcium-channel blockers, centrally acting alphaadrenergic blockers, and direct vasodilators. At the start of the cohort phase, the blood-pressure target was less than 140/90 mm Hg. The target was reduced to less than 130/80 mm Hg in 2004, just after national guidelines recommended this target.9 (link)
Appel L.J., Wright JT J.r., Greene T., Agodoa L.Y., Astor B.C., Bakris G.L., Cleveland W.H., Charleston J., Contreras G., Faulkner M.L., Gabbai F.B., Gassman J.J., Hebert L.A., Jamerson K.A., Kopple J.D., Kusek J.W., Lash J.P., Lea J.P., Lewis J.B., Lipkowitz M.S., Massry S.G., Miller E.R., Norris K., Phillips R.A., Pogue V.A., Randall O.S., Rostand S.G., Smogorzewski M.J., Toto R.D, & Wang X. (2010). Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease. The New England journal of medicine, 363(10), 918-929.
Publication 2010
Adrenergic alpha-Antagonists Adrenergic beta-Antagonists Amlodipine Angiotensin-Converting Enzyme Inhibitors Angiotensin Receptor Antagonists Antihypertensive Agents Blood Pressure Calcium Channel Blockers Chronic Kidney Diseases Clinical Investigators Clonidine Dihydropyridines Doxazosin Furosemide Hydralazine Kidney Failure, Chronic Metoprolol Minoxidil Patients Pharmaceutical Preparations Pharmacotherapy Ramipril Therapeutics Vasodilator Agents
3
Assessing ACE Inhibitor Exposure Impact
Cited 4 times
The predictor of interest was cumulative exposure to ACE inhibitors. Participants brought in all medications used in the prior two weeks and each was recorded by study staff. ACE inhibitors were classified into two groups according to their ability to cross the blood brain barrier. These determinations were made based primarily on experiments in rats. The two most common means of measuring ability to cross the blood brain barrier were 1) analysis of ground up, tissue specific ACE activity after administration of ACE inhibitors orally or subcutaneously and 2) tissue specific imaging of a radio-labeled ACE inhibitor after administration of various ACE inhibitors (which compete for binding with the radio-labeled ACE inhibitor).After review of the literature and pharmaceutical package inserts, captopril, fosinopril, lisinopril, perindopril, ramipril, and trandolapril were classified as crossing the blood brain barrier, while benazepril, enalapril, moexapril, and quinapril were classified as not (Box). 20 (link)–28 (link) If data on use of ACE inhibitors were missing for an examination, and the values before and after that examination agreed, the missing value was replaced with the value observed for those visits. If data for more than two visits were missing, no imputations of missing data were attempted. Only 1.3% of the values were imputed.
Sink K.M., Leng X., Williamson J., Kritchevsky S.B., Yaffe K., Kuller L., Yasar S., Atkinson H., Robbins M., Psaty B, & Goff DC J.r. (2009). Angiotensin Converting Enzyme Inhibitors and Cognitive Decline in Older Adults with Hypertension: Results from the Cardiovascular Health Study. Archives of internal medicine, 169(13), 1195-1202.
Publication 2009
Angiotensin-Converting Enzyme Inhibitors benazepril Blood-Brain Barrier Captopril Enalapril Fosinopril inhibitors Lisinopril Perindopril Pharmaceutical Preparations Quinapril Ramipril Rattus Tissue Specificity trandolapril
4
Electrically Stimulated Right Atrium Samples
Cited 3 times
Right atrium (RA) samples were obtained from patients undergoing open-heart surgery with coronary artery bypass grafts and electrically stimulated in organ baths as described previously (Gergs et al., 2008 (link); Gergs et al., 2013 (link); Gergs et al., 2018 (link)). Patients were treated with the following drugs: acetyl salicylic acid (ASS), clopidogrel, bisoprolol, thyroxine, atorvastatin, pantoprazole, olmersartan, amlodipine, frusemide, metformin, rivaroxaban, ipratropiumbromide, fenoterol, simvastatin, torasemide, esomeprazole, flucatison, salmeterol, ramipril, and hydrochlorothiazide. Patients were in CCS (Canadian Cardiovascular Society, angina classification) scale from III to IV and NYHA (New York Heart Association, heart failure classification) class II–III. Left ventricular ejection fraction ranged from 40 to 55%. This study complied with the Declaration of Helsinki and was approved by the local ethics committee (hm-bü 04.08.2005). All patients gave informed consent.
Boknik P., Drzewiecki K., Eskandar J., Gergs U., Hofmann B., Treede H., Grote-Wessels S., Fabritz L., Kirchhof P., Fortmüller L., Müller F.U., Schmitz W., Zimmermann N., Kirchhefer U, & Neumann J. (2019). Evidence for Arrhythmogenic Effects of A2A-Adenosine Receptors. Frontiers in Pharmacology, 10, 1051.
Full text: Click here
Publication 2019
Amlodipine Angina Pectoris Aspirin Atorvastatin Atrium, Right Bath Bisoprolol Cardiovascular System Clopidogrel Congestive Heart Failure Coronary Artery Bypass Surgery Electricity Esomeprazole Fenoterol Furosemide Heart Hydrochlorothiazide Metformin Pantoprazole Patients Pharmaceutical Preparations Ramipril Regional Ethics Committees Rivaroxaban Salmeterol Simvastatin Thyroxine Torsemide Ventricular Ejection Fraction
5
Rat model of chronic kidney disease
Cited 3 times
Experimental procedures were performed in accordance with the National Health and Medical Research Council of Australia guidelines for animal experimentation, and were approved by the Animal Ethics Committee, Austin Health. Rats were housed in a 12 h/12 h light/dark cycle, with ad libitum food containing 0.4–0.6% NaCl (Norco) and water. STNx (n=21) or sham surgery (Controls; n=21) was performed in female Sprague–Dawley rats (body weight, 200–250 g), as described previously [23 (link)]. In brief, rats were anaesthetized by intraperitoneal injection of sodium pentobarbitone (60 mg/kg of body weight; Boehringer Ingelheim) and STNx was performed by right nephrectomy, followed by infarction of approximately two-thirds of the left kidney with selective ligation of all but one of the extrarenal branches of the left renal artery. Rats were randomly allocated to a vehicle-treated group (n=10 for Control; n=9 for STNx) or an ACEI-treated group (n=11 for Control; n=12 for STNx) for 10 days. The ACEI ramipril was administered by daily gavage at a dose of 1 mg/kg of body weight. On day 9, rats were housed in metabolic cages for 24 h to measure water intake and urine output, and to collect samples of urine for biochemical analysis and protein analysis. On day 10, rats were anaesthetized by intraperitoneal injection of sodium pentobarbitone (60 mg/kg of body weight), and SBP [systolic BP (blood pressure)] was measured via carotid artery cannulation. Rats were then killed by a lethal dose of sodium pentobarbitone. The remnant kidney was removed and weighed. A portion of the kidney was fixed in 4% paraformaldehyde and embedded in paraffin for histopathology. The remainder of the kidney was snap-frozen in 2-methylbutane and stored at −80°C for the in vitro autoradiographic studies, ACE2 activity assay and RNA extraction.
Velkoska E., Dean R.G., Burchill L., Levidiotis V, & Burrell L.M. (2009). Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition. Clinical Science (London, England : 1979), 118(Pt 4), 269-279.
Publication 2009
ACE2 protein, human Animal Ethics Committees austin Biological Assay Blood Pressure Body Weight Cannulation Common Carotid Artery Females Food Freezing Infarction Injections, Intraperitoneal isopentane Kidney Ligation Nephrectomy Operative Surgical Procedures Paraffin Embedding paraform Pentobarbital Sodium Proteins Ramipril Rats, Sprague-Dawley Rattus Renal Artery Sodium Chloride Systolic Pressure Tube Feeding Urine Water Consumption

Most recents protocols related to «Ramipril»

1
Rare HIV-1 Controller with Antiretroviral Resistance
The 59- year-old controller (subject #1) was diagnosed with HIV-1 infection when he was treated in the hospital for recurrent epileptic seizures. Since an ischemic stroke seven years previously he had suffered from hemiparesis of his right leg and right arm. He was a smoker with hypertonic blood pressure. The time point of HIV-1 infection is not known but was established to have occurred prior to his severe neurological disability.
At diagnosis, he displayed a CD4 count of 1004 cells/µL and HIV-1-specific antibodies measured by ELISA (ARCHITECT HIV Ag/Ab Combo Assay, Abbott, Wiesbaden, Germany) and immunoblot (Geenius HIV 1/2 Confirmatory Assay, Bio-Rad laboratories, Feldkirchen, Germany). He maintained normal CD4 counts >800 cells/µL over the next 453 days post-diagnosis (Table 1). His viral load measured by real-time HIV-1 PCR (Abbott RealTime HIV-1 assay, Abbott, Wiesbaden) was 40 copies/mL at diagnosis. with subsequent low viral loads ranging between <20 and 20 copies/mL until day 293 post-diagnosis (Table 1). At day 383, four weeks after a traumatic subarachnoid hemorrhage and fracture of his right humerus, he displayed a transient increase of viral load to 250 copies/mL with spontaneous decline to <20 copies/mL at day 453. A resistance analysis from plasma obtained at day 383 post-diagnosis revealed the presence of several mutations in reverse transcriptase (RT, 41L, 210W, 215A) and protease (33F, 43T, 46L, 53L, 82A, 88D) which were associated with high-level resistance against zidovudine, stavudine and several protease inhibitors. This indicated the transmission of a drug-resistant virus as the patient has not been treated with antiretroviral drugs in the past.
At the time point of his first viral load measurement, he was treated with the following drugs: lamotrigine, levetiracetam, lacosamide, simvastatin, acetylsalicylic acid, ramipril, amlodipine, melperone, baclofen, citalopram and thiamine. The patient’s HLA-type was HLA A*11, B*52, B*57, C*6, C*12.
In addition to the controller (subject #1), we investigated 14 HLA-B*52-positive, HIV-1-infected patients (clinical characteristics shown in Table S1). All were on antiretroviral combination therapy (cART) for a median time of 75 months (range 3–315 months). They presented with a current median viral load of <20 copies/mL (range: <20 to 40 copies/mL) and a current median CD4 count of 872 (range 351–1434).
El Kenz B., Schmidt K.G., Ogungbemi-Alt V.K., Bergmann S., Steininger P., Korn K., Spriewald B., Harrer E.G., Nganou-Makamdop K, & Harrer T. (2023). Definition of a New HLA B*52-Restricted Rev CTL Epitope Targeted by an HIV-1-Infected Controller. Viruses, 15(2), 567.
Full text: Click here
Publication 2023
Amlodipine Aspirin Baclofen Biological Assay Blood Pressure CD4+ Cell Counts Cells Citalopram Combination Antiretroviral Therapy Diagnosis Disabled Persons Enzyme-Linked Immunosorbent Assay Epilepsy Hemiparesis HIV-1 HIV-2 HIV Antibodies HIV Infections HLA-B Antigens HLA Typing Humeral Fractures Immunoblotting Infection Lacosamide Lamotrigine Levetiracetam metylperon Mutation Patients Peptide Hydrolases Pharmaceutical Preparations Plasma Protease Inhibitors Ramipril Real-Time Polymerase Chain Reaction RNA-Directed DNA Polymerase Simvastatin Stavudine Stroke, Ischemic Subarachnoid Hemorrhage, Traumatic Thiamine Transients Transmission, Communicable Disease Virus Zidovudine
2
Evaluating COVID-19 Patients' Characteristics
Patients were recruited from University Hospital Coventry and Warwickshire (UHCW), an 1100 bed tertiary UK hospital in the West Midlands, UK. The COVID-19 positive, symptomatic group were patients that were admitted based on respiratory symptoms and were then found to be COVID-19 positive based on a PCR test. Asymptomatic patients were identified through regular SARS-CoV-2 screening in accordance with the national guidelines at the time. COVID-19 negative patients (control arm) were identified from patients entering hospital for surgery associated with non-infectious conditions (for example, a prostate biopsy). These patients received a SARS-CoV-2 PCR test prior to admission to the hospital. The patients were reviewed for eligibility, consented to enter the study and were given a patient information leaflet. A letter detailing recruitment was then sent to their general practitioner. Demographic data collected included the age, gender, nationality, smoker status, medications they were currently prescribed and SARS-CoV-2 vaccination status of the patient. The most common medications the participants were prescribed were paracetamol, bisoprolol, omeprazole, AdCal D3, a statin, metformin, amlodipine, ramipril and sertraline. These drugs were seen in all the groups. In total, 85 patients were recruited into the study. Table 1 provides the demographic breakdown of the patient groups.
Laird S., Debenham L., Chandla D., Chan C., Daulton E., Taylor J., Bhat P., Berry L., Munthali P, & Covington J.A. (2023). Breath Analysis of COVID-19 Patients in a Tertiary UK Hospital by Optical Spectrometry: The E-Nose CoVal Study. Biosensors, 13(2), 165.
Full text: Click here
Publication 2023
Acetaminophen Amlodipine Biopsy Bisoprolol Catabolism Communicable Diseases COVID 19 Eligibility Determination Gender Hospital Admission Tests Hydroxymethylglutaryl-CoA Reductase Inhibitors Metformin Omeprazole Operative Surgical Procedures Patients Pharmaceutical Preparations Prostate Ramipril SARS-CoV-2 Sertraline Signs and Symptoms, Respiratory Vaccination Vision
3
Diabetic Nephropathy Intervention
Patients were recruited from Internal Medicine Department, Tanta University Hospital, Tanta, Egypt. Eligible patients were aged ≥ 18 years with a confirmed diagnosis of type 2 diabetes mellitus at least 6 months before screening and had stage 2 or 3 diabetic nephropathies (persistent micro- or macroalbuminuria UACR > 30 mg/g) despite treatment with a maximum tolerated dose of ramipril for at least eight weeks before recruitment. Exclusion criteria were Type 1 diabetes mellitus, severe renal impairment (eGFR < 30 mL/min/1.73 m2), pregnancy or lactation, chronic heart failure, malignancy, inflammatory or autoimmune disease, and history of kidney disease other than diabetic nephropathy.
El-fatatry B.M., El-Haggar S.M., Ibrahim O.M, & Shalaby K.H. (2023). Niclosamide from an anthelmintic drug to a promising adjuvant therapy for diabetic kidney disease: randomized clinical trial. Diabetology & Metabolic Syndrome, 15, 22.
Full text: Click here
Publication 2023
Autoimmune Diseases Breast Feeding Congestive Heart Failure Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus, Non-Insulin-Dependent Diabetic Nephropathy Diagnosis EGFR protein, human Inflammation Kidney Diseases Malignant Neoplasms Patients Pregnancy Ramipril Renal Insufficiency
4
Niclosamide Therapy in Diabetic Kidney Disease
This study was an open-labeled randomized controlled parallel clinical study designed to investigate the role of niclosamide in DKD. Eligible patients were randomly assigned to the niclosamide arm or the control arm. Randomization was carried out based on the days of the hospital visit every week. Patients in the niclosamide arm received ramipril plus niclosamide 1 g once daily, and patients in the control arm received ramipril only for 6 months. Ramipril was chosen as it is routinely used as standard therapy for diabetic patients with albuminuria in Internal Medicine Department, Tanta University Hospital, Tanta, Egypt.
El-fatatry B.M., El-Haggar S.M., Ibrahim O.M, & Shalaby K.H. (2023). Niclosamide from an anthelmintic drug to a promising adjuvant therapy for diabetic kidney disease: randomized clinical trial. Diabetology & Metabolic Syndrome, 15, 22.
Full text: Click here
Publication 2023
Niclosamide Patients Ramipril
5
QT Interval Changes in HER2+ Breast Cancer
In this prospective cohort study, we investigated 65 women with metastatic (HER2+) breast cancer treated in our Department of Medical Oncology, University Hospital Centre Zagreb, Croatia. All patients underwent treatment with the standard chemotherapy regimen which included paclitaxel and cisplatin. Thirty-nine women were excluded from the second-line treatment due to poor clinical condition or fatal outcome. We gathered data from 26 patients who continued treatment with the specific antibody drug. The average age of our subjects was 57.96 years (± 7.48 years). Eligible patients were treated with six cycles of trastuzumab, as a first-line antibody drug treatment, followed by six cycles of trastuzumab emtansine as a second-line antibody drug treatment protocol, which is the standard in our institution. Both drugs were administered subcutaneously. Only 24 patients with preserved LVEF received the second-line treatment with the antibody drug, trastuzumab emtansine after six months since two patients had LVEF reduction, In addition, one patient developed left bundle branch block, and the other one reached the age limit (70 years). The electrocardiogram was obtained and analyzed before each drug application, and six months after the last application of trastuzumab and trastuzumab emtansine (mean heart rate 72 ± 12/min). Corrected QT values were calculated using Fridericia’s formula (QTc = QT interval/3√(60/heart rate). At the time of the ECG recordings, the patients were not on any antiarrhythmics, beta blockers, psychoactive drugs or antibiotics that could influence QT interval duration. All patients had normal serum sodium and potassium levels. Three women had diabetes and were treated with insulin, four women had arterial hypertension and were treated with the ACE inhibitor Ramipril and the Calcium channel blocker Amlodipine. The other patients had no comorbidities. Before the first application of trastuzumab and trastuzumab emtansine, as well as six months after the last cycle, an echocardiogram was performed in order to assess LVEF using the biplane Simpson’s method. Data was presented as frequencies, mean with standard deviation (SD) and median with 5th and 95th percentiles, as appropriate. For statistical analysis we used Student's t-test of paired samples to compare QTc intervals before each cycle and after the last application of both drugs. The Bayesian Pearson correlation test was used to examine the correlation between QTc intervals and LVEF. A statistically significant p-value of < 0.05 was used.
Levicki R., Lovrić Benčić M., Ivanac Vranešić I., Bradić L., Begovac M., Jug J, & Dedić Plavetić N. (2023). Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer. The Egyptian Heart Journal, 75, 11.
Full text: Click here
Publication 2023
Ado-Trastuzumab Emtansine Adrenergic beta-Antagonists Amlodipine Angiotensin-Converting Enzyme Inhibitors Anti-Arrhythmia Agents Antibiotics, Antitubercular Calcium Channel Blockers Cisplatin Diabetes Mellitus Echocardiography ERBB2 protein, human Fatal Outcome High Blood Pressures Immunoglobulins Insulin Left Bundle-Branch Block Malignant Neoplasm of Breast Paclitaxel Patients Pharmaceutical Preparations Pharmacotherapy Potassium Psychotropic Drugs Ramipril Rate, Heart Serum Sodium Training Programs Trastuzumab Treatment Protocols Woman

Top products related to «Ramipril»

1
Ramipril by Merck Group
Sourced in United States, France, United Kingdom
Ramipril is an angiotensin-converting enzyme (ACE) inhibitor used in the treatment of hypertension and congestive heart failure. It works by inhibiting the conversion of angiotensin I to angiotensin II, thereby reducing blood pressure.
2
Valsartan by Novartis
Sourced in Switzerland, China
Valsartan is a pharmaceutical product used as a lab equipment. It is a synthetic angiotensin II receptor antagonist that blocks the effects of angiotensin II, a hormone that regulates blood pressure.
3
Formic acid by Merck Group
Sourced in Germany, United States, Italy, United Kingdom, France, Spain, China, Poland, India, Switzerland, Sao Tome and Principe, Belgium, Australia, Canada, Ireland, Macao, Hungary, Czechia, Netherlands, Portugal, Brazil, Singapore, Austria, Mexico, Chile, Sweden, Bulgaria, Denmark, Malaysia, Norway, New Zealand, Japan, Romania, Finland, Indonesia
Formic acid is a colorless, pungent-smelling liquid chemical compound. It is the simplest carboxylic acid, with the chemical formula HCOOH. Formic acid is widely used in various industrial and laboratory applications.
4
Hptlc silica gel 60 f254 by Merck Group
Sourced in Germany
HPTLC Silica gel 60 F254 is a thin-layer chromatography (TLC) plate coated with silica gel. It is designed for high-performance thin-layer chromatography (HPTLC) applications. The silica gel layer contains a fluorescent indicator, F254, which allows for the detection of separated compounds under ultraviolet (UV) light.
5
Scopolamine by Merck Group
Sourced in United States, United Kingdom, Germany, Sao Tome and Principe, France, India, China
Scopolamine is a chemical compound used in various laboratory applications. It functions as a muscarinic antagonist, which means it blocks the effects of the neurotransmitter acetylcholine on muscarinic receptors. This property makes it useful in research and scientific experiments, but its specific applications and intended uses should not be extrapolated upon.
6
Ramipril by Sanofi
Sourced in Australia
Ramipril is a pharmaceutical product manufactured by Sanofi. It is an angiotensin-converting enzyme (ACE) inhibitor used in the treatment of hypertension, heart failure, and other cardiovascular conditions. The core function of Ramipril is to inhibit the conversion of angiotensin I to angiotensin II, thereby reducing blood pressure and improving cardiovascular function.
7
Perindopril by Merck Group
Sourced in United States
Perindopril is a laboratory instrument used for analyzing and measuring various chemical and biochemical compounds. It functions as a high-performance liquid chromatography (HPLC) system, which is a widely used analytical technique for the separation, identification, and quantification of complex mixtures. The core function of Perindopril is to provide accurate and reliable data on the composition and properties of the samples being analyzed.
8
Hptlc diol f254 by Merck Group
Sourced in Germany
HPTLC diol F254 is a high-performance thin-layer chromatography (HPTLC) plate designed for the separation and analysis of a wide range of organic compounds. The plate features a diol-modified silica gel stationary phase and a fluorescent indicator, making it suitable for both normal-phase and reversed-phase chromatography. The fluorescent indicator, F254, allows for the visualization of separated compounds under UV light.
9
Methanol by Merck Group
Sourced in Germany, United States, Italy, India, United Kingdom, China, France, Poland, Spain, Switzerland, Australia, Canada, Sao Tome and Principe, Brazil, Ireland, Japan, Belgium, Portugal, Singapore, Macao, Malaysia, Czechia, Mexico, Indonesia, Chile, Denmark, Sweden, Bulgaria, Netherlands, Finland, Hungary, Austria, Israel, Norway, Egypt, Argentina, Greece, Kenya, Thailand, Pakistan
Methanol is a clear, colorless, and flammable liquid that is widely used in various industrial and laboratory applications. It serves as a solvent, fuel, and chemical intermediate. Methanol has a simple chemical formula of CH3OH and a boiling point of 64.7°C. It is a versatile compound that is widely used in the production of other chemicals, as well as in the fuel industry.
10
Sacubitril valsartan by Novartis
Sourced in United States, Switzerland
Sacubitril/valsartan is a combination medication that acts as an angiotensin II receptor blocker (ARB) and neprilysin inhibitor. It is used to treat heart failure with reduced ejection fraction.

More about "Ramipril"

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor medication used to manage hypertension, heart failure, and diabetic kidney disease.
It works by relaxing blood vessels and reducing the workload on the heart.
PubCompare.ai is a powerful tool that helps researchers optimize Ramipril protocols by locating the most effective approaches from literature, pre-prints, and patents.
Its AI-driven comparisons identify the best protocols and products, enhancing the research process.
Ramipril is closely related to other ACE inhibitors like Perindopril and Valsartan, which are also used to treat cardiovascular conditions.
The active ingredient, Formic acid, is a key component that enables Ramipril's mechanism of action.
HPTLC (High-Performance Thin-Layer Chromatography) techniques using Silica gel 60 F254 and HPTLC diol F254 are often employed to analyze and quantify Ramipril and its metabolites.
Scopolamine may sometimes be used in conjunction with Ramipril to manage certain symptoms, while Methanol is a common solvent used in Ramipril formulations.
Sacubitril/valsartan is another medication that may be prescribed alongside Ramipril for the treatment of heart failure.
Explore the power of AI-driven research protocol enhancment with PubCompare.ai to optimize your Ramipril studies and drive your research forward more efficiently.